RE:RE:Roche CD47 antibody start-up gives up-lays off all employeesPfizer acquisition of Trillium Therapeutics CD47 for US$2.3 Billion can potentially see ONCYs pelareorep combined with Pfizers CD47, bispecifics, CD4/6 and PARP inhibitors along with the ADCs that will come from Pfizers upcoming acquisition of Seagen, as previously outlined.
[ Pfizers Elrexfio, and J&J/Janssens Tecvayli and Talvey are off-the-shelf drugs called “bispecific” antibodies, binding to proteins on both diseased cells and T cells to trigger an immune response. They are given for as long as patients can tolerate and their disease remains in check.] https://www.biopharmadive.com/news/pfizer-bispecific-fda-approval-myeloma-bcma-elrexfio/690821/
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-trillium-therapeuticsave
https://www.biospace.com/article/pfizer-bispecific-drug-wins-fda-accelerated-approval-for-multiple-myeloma/